CN1248722C - 治疗冠心病的药物及其制备方法 - Google Patents
治疗冠心病的药物及其制备方法 Download PDFInfo
- Publication number
- CN1248722C CN1248722C CN 02128080 CN02128080A CN1248722C CN 1248722 C CN1248722 C CN 1248722C CN 02128080 CN02128080 CN 02128080 CN 02128080 A CN02128080 A CN 02128080A CN 1248722 C CN1248722 C CN 1248722C
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- rhizoma
- radix
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title description 5
- 241000218176 Corydalis Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims description 111
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000000284 extract Substances 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 239000000706 filtrate Substances 0.000 claims description 29
- 239000000796 flavoring agent Substances 0.000 claims description 24
- 235000019634 flavors Nutrition 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 230000006837 decompression Effects 0.000 claims description 16
- 238000004821 distillation Methods 0.000 claims description 16
- 238000004064 recycling Methods 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 239000012567 medical material Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000001256 steam distillation Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 229940075582 sorbic acid Drugs 0.000 claims description 5
- 235000010199 sorbic acid Nutrition 0.000 claims description 5
- 239000004334 sorbic acid Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 241000545442 Radix Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 18
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 4
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 49
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 31
- 229960004166 diltiazem Drugs 0.000 description 31
- 208000002193 Pain Diseases 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000036581 peripheral resistance Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 241000628997 Flos Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 240000005578 Rivina humilis Species 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- -1 dry below 60 °C Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种以中草药为原料制成的中药组合物,具体地说,本发明涉及一种治疗冠心病的中药;本发明还涉及该组合物的制备方法。本发明的目的是克服现有技术的不足,提供一种既补益正气,又活血化瘀的治疗冠心病的药物。本发明提供一种治疗冠心病的药物,是由下述重量配比的原料组成的药剂:黄芪1-12份;莪术1-10份;黄精1-12份;丹参1-10份;川芎1-10份;当归1-8份;延胡索1-10份;乌药1-8份。
Description
技术领域
本发明涉及一种以中草药为原料制成的中药组合物,具体地说,本发明涉及一种治疗冠心病的中药;本发明还涉及该组合物的制备方法。
背景技术
冠心病心绞痛为临床常见病、多发病,中老年罹患者尤多。其病因病机非止一端,但以气虚血瘀,本虚标实为基本病机。中老年人,正气渐衰,气为血帅,心气不足,推动无力,可导致血行不畅,日久则致心血瘀阻。心血瘀阻既是病理产物,又可作为病因进一步阻碍气血的正常运行,加重心脉不通。同时,外感寒邪是诱发和加重胸痹的重要因素,“寒主收引”,寒则血行滞涩,加重气滞血瘀,阻痹心脉。本病属于正气亏虚为本,血淤、气滞、寒凝、痰浊为标的本虚标实之证。在标实之中,尤以血脉瘀阻为突出。临床以胸部刺痛、绞痛,固定不移,或胸部隐痛,时作时止,心悸气短,神疲乏力,舌质紫暗或淡紫,脉沉弦或细弱无力等为证候特征。2000版中国药典一部收载的舒心口服液,其组方:党参、黄芪、红花、当归、川芎、三棱、蒲黄,用于气虚血瘀所致的胸闷胸痛,气短乏力;冠心病、心绞痛见有上述证候者。2000版中国药典一部收载的精制冠心片,丹参、赤芍、川芎、红花、降香,用于心血瘀阻之冠心病,心绞痛。2000版中国药典一部收载,专利申请号01136155.7的复方丹参滴丸由丹参、三七、冰片三味药组成,具有活血化瘀、理气止痛的作用,但主要还是以气滞血瘀为主。以上中成药均有一定的不足之处,或偏于益气,或偏于通阳,或偏于活血,既补益正气,又活血化瘀的治疗冠心病的药物。
发明内容
本发明的目的是克服现有技术的不足,提供一种既补益正气,又活血化瘀的治疗冠心病的药物。本方以益气化瘀,温通止痛为治法。针对胸痹以正气虚弱为本,瘀血阻络为标,胸闷胸痛为主要临床症状,故以补益正气治本,活血化瘀治标,同时兼顾温通止痛为法。
本发明的技术方案是:
本发明药物由下列重量配比的原料制成:
黄 芪1-12份 莪 术1-10份 黄 精1-12份 丹 参1-10份
川 芎1-10份 当 归1-8份 延胡索1-10份 乌 药1-8份
以上述重量配比的原料制备成临床上需要的任何口服药剂。
本发明药物补益正气之时兼用理气行气之品,活血化瘀之中兼寓养血生新之功,在针对主要病因病机的同时,并兼温通止痛、化瘀止痛、行气止痛以缓解主要症状,攻补兼施,标本同治,补而无壅滞之弊,通而无伤正之虞,组合有序,故为有制之师。
功能主治:益气化瘀,温通止痛,适用于正气不足,心血瘀阻所致的胸部刺痛、绞痛,固定不移,入夜更甚,或胸部隐痛,时作时止,心悸气短,神疲乏力,舌质紫暗或淡紫,脉沉弦或细弱等症。即冠心病心绞痛见上述证候者。
具体实施方式
本发明药物由下列重量配比的原料制成:
黄 芪1-12份、莪 术1-10份、黄 精1-12份、丹 参1-10份、
川 芎1-10份、当 归1-8份、 延胡索1-10份、乌 药1-8份。
制备本发明药物的优选重量配比范围是:
黄 芪2-10份、莪 术2-8份、黄 精2-10份、丹 参2-8份、
川 芎2-8份、 当 归2-6份、延胡索2-8份、 乌 药2-6份。
本发明药物的最佳重量比是:
黄 芪6份、莪 术5份、黄 精6份、丹 参5份、
川 芎5份、当 归4份、延胡索5份、乌 药4份。
上述的治疗冠心病的药物,是任何一种药剂学上所说的口服剂型;优选的是口服液。
上述口服液的制备方法是:
以上八味,当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml,加入药液总量0.3%吐温-80增溶,备用,蒸馏后药液另器收集;丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12(50℃),以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用;提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇继续浓缩至相对密度1.15~1.18(50℃),加入上述丹参脂溶性提取部位,煮沸,放冷滤过,滤液中加入重蒸馏芳香水,加蒸馏水调至总量,用40%NaOH溶液调pH至7,加0.2%山梨酸,分装,灭菌,即得本发明药物。
采用心外膜电图标测心肌缺血范围及其程度,定量组织学(N-BT染色法)测定心肌梗塞范围。试验结果表明:十二指肠给予本发明药物有明显改善麻醉犬急性心肌缺血和心肌梗塞面积的作用;减轻心外膜电图标测的心肌缺血程度(∑-ST)及心肌缺血范围(N-ST)。大剂量的本发明药物能显著减轻N-BT染色所显示的梗塞区。结果表明:本发明药物可显著增加冠脉血流量,降低冠脉阻力;明显增加心输出量,降低总外周阻力;明显增加心博出量、心肌指数、心脏指数。大剂量能升高左室内压及左室作功,使心脏功能得到改善。实验结果如表1-11所示。
表1本发明口服液对麻醉犬急性心肌缺血程度(∑-ST)的影响(心外膜电图标测)(
X±S)
组别 | 剂量/kg | 药前值(mv)(变化%) | 30 | 给药后值(mv)(变化%)60 | 90 | 120 | 180(min) |
生理盐水 | 5.0ml | 242.85±62.43 | 264.08±61.73 | 242.50±59.70 | 244.25±68.13 | 29.25±45.10 | 230.33±36.05 |
N=6 | 100 | 109.50±6.74 | 100.41±9.32 | 100.55±16.42 | 95.79±10.07 | 99.72±29.97 | |
本发明口服液 | 5.0g | 204.17±31.42 | 175.75±44.78 | 165.75±46.86* | 166.08±48.49* | 184.92±48.47 | 177.33±54.77 |
N=6 | 100 | 86.46±17.31# | 80.64±13.18# | 80.78±13.94# | 90.59±17.98 | 86.50±21.62 | |
本发明口服液 | 10.0g | 194.17±58.45 | 143.83±43.17** | 124.91±44.02** | 124.33±43.68* | 134.10±45.10 | 132.08±42.65* |
N=6 | 100 | 74.78±7.88## | 64.79±16.86## | 64.88±19.03## | 75.68±24.99 | 71.08±38.38 | |
硫氮卓酮 | 5.0mg | 242.83±76.60 | 169.75±62.80** | 165.33±84.42* | 175.00±83.65* | 178.50±92.35* | 159.80±90.11* |
N=6 | 100 | 69.34±8.62## | 66.74±21.11## | 70.46±15.32## | 71.08±22.17# | 65.11±25.41 |
表2本发明口服液对麻醉犬急性心肌缺血范围(N-ST)的影响(心外膜电图标测)(
X±S)
组别 | 剂量 | 药前值(点数 | 给药后值(变化% | |||||
/kg | (变化%) | 15 | 30 | 60 | 90 | 120 | 180min | |
生理盐水 | 5.0ml | 27.83±2.23 | 28.83±0.98 | 29.00±1.67 | 28.67±2.42 | 28.33±3.20 | 27.33±5.61 | 29.17±1.33 |
N=6 | 100 | 104.01±6.87 | 104.39±3.73 | 102.99±3.51 | 101.61±5.82 | 97.44±15.41 | 105.08±4.84 | |
本发明口服液 | 5.0g | 30.00±0 | 29.67±0.82 | 29.33±1.63 | 29.17±1.60 | 29.67±0.82 | 29.67±0.82 | 29.33±1.63 |
N=6 | 100 | 98.89±2.72 | 97.78±5.44 | 97.22±5.34 | 98.89±2.72 | 98.89±2.72 | 97.78±5.44 | |
本发明口服液 | 10.0g | 29.50±1.22 | 29.17±1.33 | 28.17±2.14 | 24.83±4.31* | 24.50±5.01 | 24.83±4.75* | 24.83±3.13* |
N=6 | 100 | 98.89±2.72 | 95.56±7.20# | 84.13±13.66# | 83.08±16.55# | 89.01±8.60 | 84.20±9.99# | |
硫氮卓酮 | 5.0mg | 29.83±0.41 | 28.83±1.84 | 27.83±2.56 | 28.17±2.23 | 27.00±4.47 | 26.40±5.37 | 25.00±6.93 |
N=6 | 100 | 96.61±5.25 | 93.28±8.19# | 94.43±7.50# | 90.58±14.64 | 88.55±17.62 | 83.77±22.64# |
注:与给药前比较*P<0.05;与生理盐水组比较#P<0.05
表3本发明口服液对麻醉犬急性心肌梗塞范围的影响(
X±S)(N-BT)
染色定量组织学测定
组别 | 动物数 | 剂量 | 梗塞区(g)/全心脏(g)(%) | 梗塞区(g)左心室(g)(%) |
生理盐水 | 6 | 5.0ml/kg | 11.18±3.30 | 13.9±3.92 |
本发明口服液 | 6 | 5.0g/kg | 10.86±4.17 | 12.93±4.42 |
本发明口服液 | 6 | 10.0g/kg | 7.02±1.49* | 8.58±1.83* |
硫氮卓酮 | 6 | 5.0mg/kg | 6.57±1.16* | 8.23±1.49* |
注:与生理盐水组比较*<0.05
表4-A本发明口服液对麻醉犬血压(mmHg)及心率(beats/min)的影响(
X±S)
项目 | 组别 | 剂量 | 药前值(变化%) | 给药后值(变化%) | |||||
5 | 10 | 15 | 20 | 25 | 30 | ||||
血压 | 生理盐水 | 5.0ml | 123.66±20.79 | 124.83±18.97 | 124.83±18.97 | 124.33±20.53 | 127.33±22.09 | 127.66±20.59 | 127.33±21.24 |
n=6 | 100 | 101.52±5.61 | 101.66±9.85 | 101.34±13.19 | 103.84±15.08 | 104.26±14.72 | 103.59±11.79 | ||
本发明口服液 | 5.0g | 125.33±23.47 | 123.67±21.44 | 126.17±20.65 | 128.17±21.63 | 128.67±23.63 | 131.00±27.42 | 131.83±27.38 | |
n=6 | 100 | 98.87±2.19 | 105.67±13.71 | 102.64±6.07 | 102.64±6.07 | 104.33±6.42 | 105.04±7.32 | ||
本发明口服液 | 10.0g | 116.50±26.25 | 117.66±25.22 | 117.33±23.38 | 118.66±19.89 | 117.83±17.45 | 119.16±13.73 | 119.16±14.35 | |
n=6 | 100 | 103.28±8.06 | 103.33±10.21 | 105.20±12.39 | 103.01±10.73 | 105.01±15.10 | 105.27±17.92 | ||
硫氮卓酮 | 5.0mg | 122.57±6.24 | 122.43±6.45 | 121.57±6.08 | 116.57±7.46 | 113.43±9.22 | 110.43±11.98 | 109.00±11.68* | |
n=7 | 100 | 99.97±4.12 | 99.26±4.12 | 95.12±4.15 | 92.65±7.58 | 89.00±8.78 | 88.99±9.28# | ||
生理盐水 | 5.0ml | 172.33±23.07 | 172.00±20.97 | 171.66±21.19 | 171.67±21.63 | 169.00±20.66 | 169.33±19.91 | 169.67±21.16 | |
n=6 | 100 | 99.94±1.75 | 99.73±1.59 | 99.70±1.65 | 98.22±2.76 | 98.46±2.82 | 98.58±2.41 | ||
本发明口服液 | 5.0g | 146.67±24.67 | 147.00±22.93 | 145.67±26.64 | 146.00±26.83 | 145.33±24.16 | 145.17±21.35 | 143.50±22.18 | |
n=6 | 100 | 100.46±2.48 | 99.11±2.61 | 99.33±2.92 | 99.20±3.63 | 99.49±5.96 | 98.23±5.80 | ||
本发明口服液 | 10.0g | 147.83±18.58 | 147.16±20.25 | 146.66±23.14 | 147.00±23.09 | 148.66±20.69 | 149.50±20.11 | 149.16±20.67 | |
n=6 | 100 | 99.44±2.48 | 98.97±4.44 | 99.23±4.48 | 100.57±3.36 | 101.09±3.92 | 100.82±3.93 | ||
硫氮卓酮 | 5.0mg | 157.71±19.43 | 153.14±18.47 | 149.29±17.60* | 144.29±13.84* | 139.86±10.70* | 135.14±8.93** | 128.71±9.32** | |
n=7 | 100 | 97.17±2.43 | 94.81±4.26# | 91.89±5.46## | 89.31±7.08## | 86.52±8.87## | 82.29±7.25## |
注:与给药前自身比较*P<0.05,**P<0.01;与生理盐水组比较#P<0.05,##P<0.01 表4-B本发明口服液对麻醉犬血压(mmHg)及心率(beats/min)的影响(
X±S)
项目 | 组别 | 剂量 | 药前值(变化%) | 给药后值(变化%) | ||||
45 | 60 | 75 | 90 | 120(min) | ||||
血压 | 生理盐水 | 5.0ml | 123.66±20.79 | 124.00±22.86 | 114.67±27.49 | 113.17±32.66 | 115.17±35.38 | 112.00±35.29 |
n=6 | 100 | 100.91±13.59 | 92.08±9.79 | 90.41±13.41 | 93.54±15.40 | 89.60±16.90 | ||
本发明口服液 | 5.0g | 125.33±23.47 | 131.17±38.41 | 133.00±39.46 | 126.17±33.75 | 125.67±27.21 | 119.33±24.31 | |
n=6 | 100 | 103.46±14.76 | 104.92±15.19 | 99.99±13.35 | 100.25±10.37 | 95.78±13.23 | ||
本发明口服液 | 10.0g | 116.50±26.25 | 120.83±18.42 | 118.33±22.25 | 116.66±19.31 | 113.16±18.96 | 114.50±20.03 | |
n=6 | 100 | 106.29±18.50 | 103.86±20.99 | 102.28±17.19 | 99.25±16.77 | 99.78±11.35 | ||
硫氮卓酮 | 5.0mg | 122.57±6.24 | 102.14±11.94** | 99.71±15.56** | 97.71±16.45** | 94.71±15.53** | 96.57±16.63** | |
n=7 | 100 | 83.37±9.19# | 81.44±12.39 | 79.72±12.28 | 77.37±12.39 | 78.85±12.89 | ||
生理盐水 | 5.0ml | 172.33±23.07 | 168.33±18.96 | 166.67±19.24 | 158.00±27.57 | 158.00±27.36 | 156.33±25.47 | |
n=6 | 100 | 97.99±4.52 | 96.95±3.36 | 91.31±5.20 | 91.32±5.24 | 90.41±4.58 | ||
本发明口服液 | 5.0g | 146.67±24.67 | 141.83±24.28 | 141.67±24.61 | 141.67±23.22 | 137.83±24.99 | 140.17±25.64 | |
n=6 | 100 | 96.81±5.33 | 96.68±5.12 | 96.92±7.25 | 94.11±7.42 | 95.63±6.35 | ||
本发明口服液 | 10.0g | 147.83±18.58 | 145.83±24.53 | 144.66±21.24 | 144.33±23.13 | 145.66±19.39 | 144.83±17.64 | |
n=6 | 100 | 98.22±5.93 | 97.82±7.76 | 97.65±9.70 | 98.84±9.53 | 98.44±9.89 | ||
硫氮卓酮 | 5.0mg | 157.71±19.43 | 117.71±12.12** | 112.00±15.33** | 112.00±17.35** | 111.71±19.15** | 108.14±18.91** | |
n=7 | 100 | 75.10±7.05## | 71.21±6.69## | 71.18±7.90## | 70.99±9.24## | 68.83±9.96** |
注:与给药前自身比较*P<0.05,**P<0.01;与生理盐水组比较#P<0.05,##P<0.01 表5-A本发明口服液对麻醉犬冠脉血流量(ml/100g.min).冠脉阻力(mmHg/ml/100g.min)的影响(
X±S)
项目 | 组别 | 剂量/kg | 药前值变化% | 给药后值 | |||||
5 | 10 | 15 | 20 | 25 | 30 | ||||
生理盐水n=6 | 5.0ml | 137.67±35.55100 | 130.67±35.0095.61±15.92 | 128.20±35.9393.73±16.03 | 118.86±39.4185.97±14.10 | 127.03±31.6389.66±9.58 | 123.43±36.6389.64±10.02 | 118.17±29.5386.40±8.26 | |
本发明口服液n=6 | 5.0g | 121.02±12.52100 | 130.86±6.77*108.06±6.86 | 134.14±13.68*111.14±8.24# | 135.10±15.15*111.88±9.22## | 135.79±17.60*112.15±8.28# | 144.51±30.06*119.39±21.94# | 137.62±20.27*113.56±10.31## | |
本发明口服液n=6 | 10.0mg | 128.24±14.24100 | 140.37±21.79*109.2±8.09 | 13.74±9.96*112.89±11.52# | 147.58±17.37*115.52±11.38## | 152.62±17.36*119.95±17.29## | 153.58±13.63*120.78±16.31## | 151.30±9.42*119.42±17.51## | |
硫氮卓酮n=7 | 5.0mg | 106.89±35.64100 | 130.22±4456**122.45±65## | 135.72±39.80**130.65±19.90## | 144.86±27.83**144.78±36.98## | 153.77±29.18**153.50±43.53## | 145.36±31.76**144.09±39.95## | 149.40±32.72**147.99±38.82## | |
生理盐水n=6 | 5.0ml | 0.93±017100 | 1.00±0.2310.59±18.33 | 1.02±0.24110.45±15.91 | 1.11±0.27119.39±14.35 | 1.08±0.28115.76±12.56 | 1.08±0.26116.27±11.58 | 1.11±0.20119.98±9.81 | |
本发明口服液n=6 | 5.0g | 1.04±0.13100 | 0.95±0.13*91.70±5.98 | 0.95±0.16*91.42±8.63# | 0.96±0.1891.93±8.83## | 0.93±0.2489.28±16.98## | 0.96±0.2191.99±11.27## | 0.97±0.2192.49±13.57## | |
本发明口服液n=6 | 10.0mg | 0.91±0.20100 | 0.85±0.20*93.40±5.33 | 0.82±0.18**90.75±2.16# | 0.81±0.16*89.98±16.33## | 078±0.16*86.68±10.23## | 0.78±0.1487.75±16.38## | 0.79±0.1388.94±15.27## | |
硫氮卓酮n=7 | 5.0mg | 1.27±0.45100 | 1.04±0.38*82.08±7.08# | 0.95±0.23**77.19±9.42## | 0.82±1.15*68.92±15.16## | 0.76±0.17*64.49±18.15## | 0.79±0.19*66.73±18.19# | 0.76±0.18*63.87±18.02## |
注:给药前后自身比较*p<.05 **p<0.01与生理盐水组比较#p<0.05 ##P<0.01
表5-B本发明口服液对麻醉犬冠脉血流量(ml/100g.min).冠脉阻力(mmHg/ml/100g.min)的影响(
X±S)
项目 | 组别 | 剂量/kg | 药前值变化% | 给药后值 | ||||
45 | 60 | 75 | 90 | 120 | ||||
生理盐水n=6 | 5.0ml | 137.67±35.55100 | 124.13±32.4790.05±6.04 | 123.92±37.5089.27±10.27 | 118.39±33.4585.65±9.04 | 120.11±28.6287.84±11.01 | 107.50±27.9978.24±12.74 | |
本发明口服液n=6 | 5.0g | 121.02±12.52100 | 141.82±20.82#117.14±12.45## | 133.21±20.61110.04±13.08# | 134.99±22.68113.35±13.98## | 134.06±22.35109.66±13.09# | 127.88±27.12105.56±19.98 | |
本发明口服液n=6 | 10.0mg | 128.24±14.24100 | 148.57±13.26*116.59±12.53## | 146.24±16.32*114.69±14.49## | 147.36±16.05*115.69±15.65## | 150.22±18.83*118.46±15.03## | 150.63±22.59118.20±19.83 | |
硫氮卓酮n=7 | 5.0mg | 106.89±35.64100 | 140.71±26.68**141.90±4466# | 140.29±29.68*141.74±49.35# | 126.80±30.59129.55±5.19# | 118.94±35.22120.69±50.81 | 110.34±22.82111.46±38012 | |
生理盐水n=6 | 5.0ml | 0.93±017100 | 1.05±0.28112.55±18.55 | 0.97±0.25104.64±17.72 | 1.00±0.30106.57±22.05 | 0.98±0.28105.28±20.94 | 1.08±0.31115.75±19.88 | |
本发明口服液n=6 | 5.0g | 1.04±0.13100 | 0.95±0.2391.06±17.33 | 1.01±0.2797.28±23.70 | 0.96±0.2692.88±23.88 | 0.96±0.2392.78±21.64 | 0.97±0.2894.82±30.18 | |
本发明口服液n=6 | 10.0mg | 0.91±0.20100 | 0.82±0.2092.09±22.30 | 082±02092.09±22.30 | 0.81±0.1889.96±18.82 | 0.76±0.2085.54±20.41 | 0.78±0.2286.79±18.72 | |
硫氮卓酮n=7 | 5.0mg | 1.27±0.45100 | 0.75±0.16*63.64±18.66## | 0.74±0.19*63.62±23.12** | 0.80±0.1969.22±26.36# | 0.84±0.2172.39±25.56# | 0.89±01877.59±26.59 |
注:给药前后自身比较*p<.05 **p<0.01与生理盐水组比较#p<0.05 ##P<0.01
表6-A本发明口服液对麻醉犬输出量(l/min).总外周阻力(mmHg/L/min)的影响
项目 | 组别 | 剂量/Kg | 药前值(变化%) | 给药后值 | |||||
5 | 10 | 15 | 20 | 25 | 30 | ||||
生理盐水n=6 | 5.0ml | 1.190±0.296100 | 1.180±0.255100.02±9.97 | 1.179±0.25499.82±10.23 | 1.141±0.29896.10±11.99 | 1.164±0.30397.93±10.42 | 1.178±0.25599.69±7.55 | 1.178±0.216100.30±8.88 | |
本发明口服液n=6 | 5.0g | 1.170±0.142100 | 1.362±.283*115.59±14.11 | 1.325±0.207*112.86±6.37# | 1.270±0.227108.13±9.92 | 1.198±0.161106.21±6.87 | 1.273±0.215108.50±8.51 | 1.265±0.203107.85±7.48 | |
本发明口服液n=6 | 10.0g | 1.395±0.218**112.47±4.98# | 1.448±0.228**116.82±5.78## | 1.525±0.212**124.21±19.63# | 1.518±0.233*123.81±22.68# | 1.572±0.259*128.10±25.26# | 1.537±0.279125.41±28.16 | 1.503±0.249122.81±26.21 | |
硫氮卓酮n=7 | 5.0mg | 1.414±0.401100 | 1.593±0.472112.69±12.62 | 1.633±0.512*115.54±15.05# | 1.630±0.498*115.81±16.53# | 1.599±0.487114.26±21.75 | 1.621±0.491116.12±24.76 | 1.613±0.498115.54±26.54 | |
生理盐水n=6 | 5.0ml | 8571.14±1955.80100 | 8702.35±1794.62102.29±11.17 | 8762.31±2175.83102.43±14.25 | 8186.90±2715.83107.22±22.08 | 9236.15±2743.09107.78±24.02 | 9007.46±2351.06105.15±17.42 | 8873.91±2139.18103.78±13.56 | |
本发明口服液n=6 | 5.0g | 8649.41±1726.11100 | 2597.00±2183.33*86.57±10.24# | 7746.67±1569.20*89.74±5.61 | 8232.22±1607.8495.99±14.80 | 8332.64±1354.8997.37±11.78 | 8310.46±1545.0296.59±9.28 | 8408.53±1618.0897.60±9.37 | |
本发明口服液n=6 | 10.0g | 8216.90±1934.83100 | 7250.41±1461.62*88.76±5.68# | 6941.49±1428.51*85.01±7.25# | 6591.46±1108.23*82.02±13.39# | 6611.24±1140.74*82.24±13.02# | 6453.01±1110.60*80.55±14.49# | 6614.09±1439.7982.43±17.15 | |
硫氮卓酮n=7 | 5.0mg | 7322.16±1691.95100 | 6549.80±1648.63*89.41±7.76 | 6356.36±1625.94*87.06±10.86 | 6066.21±1449.60*83.49±11.41# | 5979.67±1328.78*82.96±12.50# | 5778.11±1527.03*79.93±14.19# | 5793.02±1728.46*79.94±16.42# |
注:给药前后比较*P<0.05 **P<0.01;与生理盐水组比较#P<0.05 ##P<0.01
表6-B本发明口服液对麻醉犬输出量(l/min).总外周阻力(mmHg/L/min)的影响
项目 | 组别 | 剂量/Kg | 药前值(变化%) | 给药后值 | ||||
45 | 60 | 75 | 90 | 120 | ||||
生理盐水n=6 | 5.0ml | 1.190±0.296100 | 1.145±0.30496.35±11.33 | 1.107±0.29092.98±7.46 | 1.053±0.27088.87±8.85 | 1.038±0.30687.47±12.71 | 1.063±0.39588.90±17.26 | |
本发明口服液n=6 | 5.0g | 1.170±0.142100 | 1.203±0.205107.41±16.40 | 1.211±0.177105.27±4.29 | 1.166±0.17899.59±7.52 | 1.125±0.19195.90±8.99 | 1.035±0.21688.24±13.68 | |
本发明口服液n=6 | 10.0g | 1.395±0.218**112.47±4.98# | 1.478±0.253121.10±27.98 | 1.478±0.253121.10±27.98 | 1.465±0.284119.90±29.62 | 1.420±0.283115.80±27.25 | 1.322±0.197107.74±18.99 | |
硫氮卓酮n=7 | 5.0mg | 1.414±0.401100 | 1.545±0.472116.69±31.94 | 1.452±0.508103.21±24.33 | 1.327±0.31996.13±19.72 | 1.336±0.31597.34±23.71 | 1.270±0.32391.67±17.87 | |
生理盐水n=6 | 5.0ml | 8571.14±1955.80100 | 9178.36±2783.92106.70±23.57 | 8573.86±2307.4999.98±16.82 | 8813.06±2549.89103.44±25.44 | 9159.68±3108.55107.07±31.79 | 9118.59±3392.78106.32±36.17 | |
本发明口服液n=6 | 5.0g | 8649.41±1726.11100 | 8661.87±1696.77100.45±7.91 | 8861.98±2416.59101.86±16.92 | 8755.67±2225.32101.31±19.16 | 7420.99±3541.37105.93±19.67 | 9939.25±2866.30104.66±21.83 | |
本发明口服液n=6 | 10.0g | 8216.90±1934.83100 | 6867.50±1609.3388.39±18.66 | 6791.30±1677.4386.77±30.62 | 6938.39±1710.4088.32±29.66 | 7147.56±1681.0490.28±26.54 | 7519.90±1034.2994.39±18.41 | |
硫氮卓酮n=7 | 5.0mg | 7322.16±1691.95100 | 5645.88±1573.82*78.35±16.46# | 5883.46±1469.43*81.06±12.75 | 6095.96±1330.7184.34±11.80 | 5877.49±1382.99*81.50±13.83 | 6369.88±1818.3187.75±17.84 |
注:给药前后比较*P<0.05 **P<0.01;与生理盐水组比较#P<0.05 ##P<0.01
表7-A本发明口服液对麻醉犬每搏心排出量(ml/beat)及心搏指数(ml/beat.m)的影响(
X±S)
项目 | 组别 | 剂量/kg | 药前值变化(%) | 给药后值变化(%) | |||||
心搏出量 | 5 | 10 | 15 | 20 | 25 | 30(min) | |||
生理盐水 | 5.0ml | 6.88±1.15100 | 6.83±0.94100.04±9.08 | 6.84±0.92100.27±9.15 | 6.62±1.3196.45±12.12 | 6.86±1.3499.80±10.86 | 6.95±1.16101.29±7.43 | 6.97±1.34101.73±7.95 | |
本发明口服液 | 5.0g | 8.29±2.31100 | 9.63±3.27*115.06±12.49 | 9.46±2.61*113.99±5.29 | 9.12±3.08108.95±10.43 | 8.82±2.23107.17±7.96 | 8.95±2.08109.25±8.94 | 9.03±2.19109.99±8.95 | |
本发明口服液 | 10.0g | 8.44±1.24100 | 9.67±1.35**113.06±3.43## | 9.96±1.39**118.25±6.78## | 10.62±2.69125.63±25.36# | 10.44±2.49123.55±22.47# | 10.75±2.74126.89±24.67 | 10.55±2.98124.62±28.78 | |
硫氮卓酮 | 5.0mg | 9.39±4.27100 | 10.85±4.82**115.99±13.22# | 11.39±5.27**121.88±15.37# | 11.67±5.07**126.61±21.80# | 11.72±4.84*129.49±33.66# | 11.96±4.05*135.14±41.54# | 12.77±4.86*142.69±44.64# | |
心搏指数 | 生理盐水 | 5.0ml | 11.36±2.47100 | 11.22±1.75100.09±9.09 | 11.24±1.74100.27±9.11 | 10.86±2.2296.41±12.01 | 11.32±2.7199.79±10.88 | 11.52±2.54101.66±8.18 | 11.46±2.12101.61±8.10 |
本发明口服液 | 5.0g | 12.28±2.07100 | 14.19±3.04*115.15±12.66## | 13.93±2.99*112.72±7.11## | 13.40±2.69109.02±10.31 | 13.17±2.49107.26±7.89 | 13.44±2.73109.39±8.92 | 13.50±2.50110.07±7.99 | |
本发明口服液 | 10.0g | 14.90±2.27100 | 16.81±2.35**113.08±3.42## | 17.56±2.37**118.27±6.81## | 18.66±3.85*126.03±25.06# | 18.32±3.64*123.56±22.46# | 18.79±3.95*126.91±24.66# | 18.59±4.53125.09±28.63 | |
硫氮卓酮 | 5.0mg | 13.14±2.90100 | 15.32±4.18*116.27±13.09# | 15.90±3.56**122.21±15.37# | 16.26±2.82**126.61±21.80# | 16.36±2.15*129.48±33.68* | 17.17±2.66*136.53±40.81# | 18.06±3.96*142.76±44.67# |
注:给药前后自身比较*P<0.05 **P<0.01:与生理盐水组比较#P<0.05 ##P<0.01
表7-B本发明口服液对麻醉犬每搏心排出量(ml/beat)及心搏指数(ml/beat.m)的影响(
X±S)
项目 | 组别 | 剂量/kg | 药前值变化(%) | 给药后值变化(%) | ||||
心搏出量 | 45 | 60 | 75 | 90 | 120(min) | |||
生理盐水 | 5.0ml | 6.88±1.15100 | 6.56±1.7397.83±18.90 | 6.61±1.2696.99±9.68 | 6.85±1.40103.35±21.42 | 6.82±1.65102.61±23.46 | 7.12±2.19106.46±27.63 | |
本发明口服液 | 5.0g | 8.29±2.31100 | 8.96±2.14109.09±6.95 | 8.89±2.48107.46±6.58 | 8.49±2.32103.01±8.37 | 8.44±2.37102.07±8.37 | 7.61±2.0692.69±16.38 | |
本发明口服液 | 10.0g | 8.44±1.24100 | 10.99±4.10129.82±43.26 | 11.38±5.22133.92±55.99 | 11.28±5.31132.42±56.80 | 10.05±3.13118.28±30.01 | 9.30±2.13110.38±19.63 | |
硫氮卓酮 | 5.0mg | 9.39±4.27100 | 13.44±5.12*151.22±53.29# | 13.50±6.34*146.11±37.83# | 12.29±4.38*136.53±30.08# | 12.28±4.53*135.78±29.87# | 12.26±4.53135.63±30.60 | |
心搏指数 | 生理盐水 | 5.0ml | 11.36±2.47100 | 10.90±3.6995.41±18.74 | 10.95±2.9796.16±9.96 | 11.15±3.1397.89±13.27 | 11.03±3.6496.41±16.80 | 11.57±4.9199.81±22.70 |
本发明口服液 | 5.0g | 12.28±2.07100 | 13.17±2.92106.50±11.87 | 13.16±2.38107.19±6.67 | 12.60±2.08103.09±8.29 | 12.91±2.19102.17±8.33 | 11.50±3.2193.59±15.96 | |
本发明口服液 | 10.0g | 14.90±2.27100 | 19.19±6.08129.83±43.24 | 19.81±7.88133.94±55.97 | 19.63±8.07132.42±56.81 | 17.67±4.96118.31±30.03 | 16.25±3.81110.12±19.93 | |
硫氮卓酮 | 5.0mg | 13.14±2.90100 | 19.14±5.47*151.24±53.31# | 19.00±6.56*146.00±37.98# | 17.63±5.07*136.31±30.02# | 17.47±5.03*134.80±28.66# | 17.60±5.40135.51±30.62 |
注:给药前后自身比较*P<0.05 **P<0.01;与生理盐水组比较#P<0.05 ##P<0.01
表8-A本发明口服液对麻醉犬心脏指数(l/min.mm)及心肌张力时间指数的影响(
X±S)
项目 | 组别 | 剂量/kg | 药前值变化% | 给药后值变化(%) | |||||
5 | 10 | 15 | 20 | 25 | 30(min) | ||||
心脏指数 | 生理盐水n=6 | 5.0ml | 1.979±0.634100 | 1.949±0.499100.04±9.97 | 1.949±0.504100.04±10.00 | 1.855±0.56096.12±11.99 | 1.930±0.61497.94±10.44 | 1.959±0.559100.05±8.34 | 1.950±0.483100.03±8.89 |
本发明口服液n=6 | 5.0g | 1.804±0.444100 | 2.082±0.572*115.65±14.18 | 2.056±0.601*112.89±6.34## | 1.951±0.539**108.13±9.91 | 1.927±0.537106.25±6.85 | 1.975±0.602108.50±8.51 | 1.959±0.576107.85±7.48 | |
本发明口服液n=6 | 10.0g | 2.216±0.51100 | 2.418±0.521112.48±4.95# | 2.579±0.573116.82±5.74## | 2.701±0.466124.22±19.60# | 2.688±0.478*123.82±22.69# | 2.782±0.512*128.12±25.26# | 2.732±0.533125.86±27.88 | |
硫氮卓酮n=7 | 5.0mg | 2.300±0.689100 | 2.599±0.829*112.96±12.55 | 2.658±0.871*115.83±15.14# | 2.639±0.517*116.41±16.91# | 2.584±0.786114.82±21.76 | 2.620±0.798116.15±24.78 | 2.610±0.817115.57±26.57 | |
心肌张力时间指数 | 生理盐水n=6 | 5.0ml | 122.84±31.5100 | 134.51±17.28100.70±3.46 | 146.03±16.85100.59±5.43 | 145.65±17.57100.37±7.09 | 146.25±18.34100.81±8.30 | 146.62±16.99101.15±8.22 | 146.58±18.09100.94±6.38 |
本发明口服液n=6 | 5.0g | 135.01±19.9100 | 134.41±18.9199.68±1.56 | 135.22±20.92*100.08±3.74 | 136.42±21.41**100.92±3.11 | 136.42±21.46*100.96±4.05 | 137.60±22.67101.78±3.77 | 137.30±23.39101.47±4.15 | |
本发明口服液n=6 | 10.0g | 129.68±11.1100 | 130.16±10.50100.43±2.96 | 129.74±10.21100.17±4.60 | 130.87±9.03101.17±6.10 | 131.32±6.02101.61±5.64 | 132.75±7.10102.79±7.65 | 132.66±9.52102.72±9.17 | |
硫氮卓酮n=7 | 5.0mg | 138.80±10.2100 | 136.68±9.4898.52±2.15 | 134.42±7.90*96.97±2.90 | 129.50±7.74**93.46±4.07# | 125.70±5.32**90.91±6.46# | 121.90±6.97**88.23±8.18# | 118.20±7.24**85.48±7.12## |
注:给药前后自身比较*P<0.05 **P<0.01;与生理盐水组比#P<0.05 ##P<0.01
表8-B本发明口服液对麻醉犬心脏指数(l/min.mm)及心肌张力时间指数的影响(
X±S)
项目 | 组别 | 剂量/kg | 药前值变化% | 给药后值变化(%) | ||||
45 | 60 | 75 | 90 | 120(min) | ||||
心脏指数 | 生理盐水n=6 | 5.0ml | 1.979±0.634100 | 1.853±0.72393.17±16.96 | 1.844±0.63493.00±7.46 | 1.761±0.63788.89±8.84 | 1.74±0.71687.48±12.70 | 1.794±0.89388.87±17.76 |
本发明口服液n=6 | 5.0g | 1.804±0.444100 | 1.895±0.632102.99±11.72 | 1.868±0.499103.34±5.98 | 1.795±0.46699.61±7.53 | 1.733±0.47695.97±8.99 | 1.615±0.53888.31±13.92 | |
本发明口服液n=6 | 10.0g | 2.216±0.51100 | 2.714±0.529126.01±33.79 | 2.743±0.633124.33±35.62 | 2.691±0.628121.35±33.04 | 2.508±0.497115.81±27.24 | 2.342±0.419107.75±18.97 | |
硫氮卓酮n=7 | 5.0mg | 2.300±0.689100 | 2.497±0.76211.70±31.96 | 2.352±0.843103.22±24.34 | 2.147±0.53096.15±19.73 | 2.116±0.51894.53±18.07 | 2.051±0.51791.69±17.90 | |
心肌张力时间指数 | 生理盐水n=6 | 5.0ml | 122.84±31.57100 | 144.08±18.8499.32±8.72 | 137.82±23.0894.40±6.07 | 133.40±29.6590.76±8.79 | 134.45±30.639147±9.76 | 131.02±28.3289.41±9.98 |
本发明口服液n=6 | 5.0g | 135.01±19.90100 | 136.00±30.1099.86±8.53 | 136.80±32.22100.47±8.23 | 133.44±27.8298.18±7.31 | 131.44±25.0796.93±5.68 | 129.10±23.5095.48±7.33 | |
本发明口服液n=6 | 10.0g | 129.68±11.15100 | 131.89±14.57101.96±10.98 | 130.06±17.03100.39±11.53 | 128.99±15.9899.52±10.01 | 127.81±14.9198.60±8.95 | 127.88±10.6698.72±5.14 | |
硫氮卓酮n=7 | 5.0mg | 138.80±10.22100 | 109.34±8.45**79.00±6.73## | 105.21±11.43**76.00±8.21## | 104.24±13.86**75.17±8.54## | 102.49±15.15**73.98±9.74# | 101.77±14.56**73.48±9.89# |
注:给药前后自身比较*P<0.05 **P<0.01;与生理盐水组比#P<0.05 ##P<0.01
表9-A本发明口服液对麻醉犬左室内压(mmHg).左室内压最大升速率(dp/dt max)的影响(
X±S)
项目 | 组别 | 剂量 | 药前值 | 给药后值(变化%) | |||||
左室内压 | /kg | 变化% | 5 | 10 | 15 | 20 | 25 | 30(min) | |
生理盐水 | 5.0ml | 127.83±19.84 | 128.83±16.09 | 128.83±18.08 | 128.33±19.33 | 130.67±20.60 | 131.00±20.47 | 129.67±20.96 | |
n=6 | 100 | 101.28±5.24 | 101.42±9.75 | 99.97±11.92 | 102.99±13.82 | 103.31±13.94 | 102.06±12.41 | ||
本发明口服液 | 5.0g | 134.16±21.09 | 132.83±20.82 | 134.33±19.09 | 135.00±19.21 | 137.16±20.45 | 138.50±23.66 | 138.83±24.03 | |
n=6 | 100 | 99.00±2.14 | 100.39±4.58 | 100.90±4.96 | 102.47±6.15 | 103.27±6.96 | 103.50±7.51 | ||
本发明口服液 | 10.0g | 120.83±19.80 | 125.00±17.75 | 128.17±16.06 | 129.33±14.67 | 129.00±13.28 | 132.67±11.88 | 134.17±11.96 | |
n=6 | 100 | 103.80±5.02 | 106.73±7.21 | 107.91±8.76 | 107.74±8.78 | 110.99±9.84 | 112.31±10.81 | ||
硫氮卓酮 | 5.0mg | 145.00±20.99 | 145.00±23.34 | 142.14±22.47 | 139.57±24.38 | 135.57±28.33 | 131.00±31.25* | 130.28±31.44* | |
n=7 | 100 | 99.98±6.07 | 97.96±4.57 | 95.96±4.89 | 92.88±7.58 | 89.34±8.89# | 88.84±9.04# | ||
左室内压最大上升速率 | 生理盐水 | 5.0ml | 1783.33±325.06 | 1758.33±347.01 | 1800.00±404.97 | 1818.67±372.88 | 1891.67±358.35 | 1791.67±320.03 | 1850.00±250.99 |
n=6 | 100 | 98.51±5.58 | 100.42±7.49 | 101.77±8.68 | 106.21±9.98 | 100.73±5.96 | 104.60±7.14 | ||
益气通脉 | 5.0g | 1733.33±467.61 | 1775.00±473.02 | 1783.33±440.07 | 1866.66±372.37 | 1850.00±398.74 | 1841.66±380.02 | 1833.33±441.21 | |
n=6 | 100 | 102.49±2.82 | 103.47±5.53 | 109.72±11.07 | 108.33±10.54 | 108.27±12.26 | 106.94±11.31 | ||
本发明口服液 | 10.0g | 1716.67±416.73 | 1783.33±457.89 | 1758.33±417.63 | 1791.67±407.94 | 1866.67±458.98 | 1833.33±427.39 | 1883.33±449.07 | |
n=6 | 100 | 103.94±6.95 | 102.76±5.26 | 105.09±7.79 | 109.14±8.61 | 107.39±11.89 | 110.98±15.65 | ||
硫氮卓酮 | 5.0mg | 1757.00±355.23 | 1728.77±363.84 | 1757.14±435.34 | 1728.57±390.36 | 1757.14±419.75 | 1728.57±446.14 | 1707.14±453.16 | |
n=7 | 100 | 98.51±7.67 | 99.74±12.73 | 98.64±11.70 | 100.00±11.79 | 99.01±14.04 | 97.04±15.50 |
注:给药前后自身比较*P<0.05,**P<0.01;与生理盐水组比较#P<0.05,##P<0.01
表9-B本发明口服液对麻醉犬左室内压(mmHg).左室内压最大升速率(dp/dt max)的影响(
X±S)
项目 | 组别 | 剂量 | 药前值 | 给药后值(变化%) | ||||
左室内压 | /kg | 变化% | 45 | 60 | 75 | 90 | 120(min) | |
生理盐水 | 5.0ml | 127.83±19.84 | 130.33±20.61 | 119.33±26.50 | 119.33±26.89 | 122.33±29.11 | 118.33±29.48 | |
n=6 | 100 | 102.31±9.15 | 92.81±9.61 | 92.72±9.49 | 94.93±11.06 | 93.59±13.35 | ||
本发明口服液 | 5.0g | 134.16±21.09 | 138.66±26.94 | 139.33±26.06 | 136.50±25.73 | 136.00±23.46 | 129.67±21.21 | |
n=6 | 100 | 103.01±7.75 | 103.01±7.63 | 101.61±8.30 | 101.51±942 | 101.56±9.93 | ||
本发明口服液 | 10.0g | 120.83±19.80 | 133.33±15.28 | 131.83±19.69 | 131.67±21.98 | 130.67±22.45 | 120.83±22.49 | |
n=6 | 100 | 111.52±13.02 | 109.78±12.84 | 109.29±11.11 | 108.53±12.59 | 100.26±12.27 | ||
硫氮卓酮 | 5.0mg | 145.00±20.99 | 127.14±31.36* | 118.14±33.06** | 117.14±34.08** | 114.71±34.27** | 114.86±35.65* | |
n=7 | 100 | 86.28±12.20# | 80.24±12.18# | 79.76±14.75# | 78.08±15.17 | 78.13±16.60 | ||
左室内压最大上升速率 | 生理盐水 | 5.0ml | 1783.33±325.06 | 1816.67±285.78 | 1766.67±273.25 | 1833.33±372.38 | 1783.33±421.51 | 1733.37±320.42 |
n=6 | 100 | 102.45±7.09 | 99.52±4.21 | 104.24±22.86 | 101.31±25.53 | 97.56±11.09 | ||
益气通脉 | 5.0g | 1733.33±467.61 | 1833.33±538.20 | 1833.33±591.32 | 1816.66±560.05 | 1800.00±505.96 | 1833.33±463.50 | |
n=6 | 100 | 108.58±10.79 | 107.67±10.49 | 104.07±7.34 | 103.59±5.67 | 104.98±5.64 | ||
本发明口服液 | 10.0g | 1716.67±416.73 | 1800.00±442.72 | 1733.33±366.96 | 1691.67±358.35 | 1433.33±653.19 | 1616.67±376.39 | |
n=6 | 100 | 106.09±17.64 | 102.84±17.59 | 100.10±14.52 | 104.93±19.25 | 95.54±14.47 | ||
硫氮卓酮 | 5.0mg | 1757.00±355.23 | 1628.57±438.61 | 1571.43±459.69 | 1528.57±485.50 | 1485.71±474.05 | 1457.14±472.08 | |
n=7 | 100 | 92.61±14.81 | 88.53±16.29 | 86.38±18.07 | 84.22±18.68 | 82.92±19.89 |
注:给药前后自身比较*P<0.05,**P<0.01;与生理盐水组比较#P<0.05,##P<0.01
注:给药前后自身比较*P<0.05,**P<0.01;与生理盐水组比较#P<0.05,##P<0.01
表10-A本发明口服液对麻醉犬左室作功(kg.m/min.mm)的影响
项目 | 组别 | 剂量/kg | 药前值(变化%) | 给药后值(变化%) | |||||
5 | 10 | 15 | 20 | 25 | 30(min) | ||||
生理盐水 | 5.0ml | 3.616±1.411 | 3.534±1.077 | 3.468±1.004 | 3.296±1.146 | 3.436±1.205 | 3.502±1.020 | 3.541±0.938 | |
n=6 | 100 | 100.36±11.29 | 99.04±12.98 | 92.87±13.04 | 96.48±11.68 | 99.98±12.10 | 101.87±13.84 | ||
本发明口服液 | 5.0g | 4.157±1.790 | 4.854±2.166* | 4.805±2.147* | 4.478±2.018 | 4.514±2.044 | 4.783±2.427 | 4.768±2.349 | |
n=6 | 100 | 116.86±10.77# | 114.61±9.67# | 107.63±11.24 | 107.50±10.87 | 112.39±13.19 | 112.45±12.61 | ||
本发明口服液 | 10.0g | 4.180±1.077 | 4.772±1.243** | 4.969±1.144** | 5.235±1.173** | 5.160±1.096** | 5.416±1.209* | 5.390±1.280 | |
n=6 | 100 | 114.16±5.96# | 119.70±10.69# | 127.10±20.50## | 126.25±24.61# | 132.43±28.46# | 131.84±30.53 | ||
硫氮卓酮 | 5.0mg | 4.037±1.215 | 4.569±1.514 | 4.649±1.645 | 4.423±1.501 | 4.245±1.621 | 4.186±1.606 | 4.098±1.590 | |
n=7 | 100 | 113.27±16.86 | 115.15±15.67 | 96.96±40.79 | 106.05±21.77 | 105.35±26.29 | 103.26±26.23 |
注:给药前后自身比较*P<0.05,**P<0.01;与生理盐水比较#P<0.05,##P<0.01
表10-B本发明口服液对麻醉犬左室作功(kg.m/min.mm)的影响
项目 | 组别 | 剂量/kg | 药前值(变化%) | 给药后值(变化%) | ||||
45 | 60 | 75 | 90 | 120min | ||||
生理盐水 | 5.0ml | 3.616±1.411 | 3.277±1.134 | 3.099±1.244 | 2.956±1.292 | 2.939±1.342 | 2.882±1.303 | |
n=6 | 100 | 90.84±14.42 | 85.41±7.41 | 80.93±8.42 | 80.28±8.55 | 79.22±10.85 | ||
本发明口服液 | 5.0g | 4.157±1.790 | 4.667±2.754 | 4.520±2.457 | 4.066±2.093 | 3.807±1.877 | 3.330±1.645 | |
n=6 | 100 | 103.25±25.88 | 105.38±18.82 | 95.81±15.71 | 81.03±37.53 | 79.25±11.01 | ||
本发明口服液 | 10.0g | 4.180±1.077 | 5.383±1.186 | 5.350±1.548 | 5.163±1.422 | 4.689士1.096 | 4.390±0.932 | |
n=6 | 100 | 132.86±33.51 | 131.89±43.78 | 1276.35±40.68 | 113.36±22.31 | 107.33±20.50 | ||
硫氮卓酮 | 5.0mg | 4.037±1.215 | 3.706±1.431 | 3.452±1.629 | 3.029±0.994 | 2.873±0.844* | 2.830±0.805* | |
n=7 | 100 | 94.30±31.77 | 85.88±28.29 | 78.02±24.42 | 74.36±22.55 | 73.10±20.85 |
注:给药前后自身比较*P<0.05,**P<0.01;与生理盐水比较#P<0.05,##P<0.01
表11本发明口服液对麻醉犬心肌耗氧量(ml/100g.min)及氧利用率的影响(
X±S)
观察指标 | 组别 | 剂量 | 药前值变化% | 给药30 | 后值60 | (变化%)90 | 120min |
心肌耗氧量 | 生理盐水 | 5.0ml | 19.42±1.69 | 16.59±3.58 | 16.40±3.58 | 15.53±1.43 | 14.3±2.36 |
n=6 | 100 | 85.87±16.46 | 83.75±12.56 | 80.78±13.37 | 74.65±16.48 | ||
本发明口服液 | 5.0g | 10.28±4.23 | 12.62±6.08 | 10.83±4.83 | 12.10±4.62 | 12.14±4.88 | |
n=6 | 100 | 121.35±14.82 | 103.63±11.24 | 119.89±30.18 | 122.09±43.67 | ||
本发明口服液 | 10.0g | 13.13±1.58 | 16.37±2.71 | 15.34±2.06 | 15.12±2.60 | 14.89±3.05 | |
n=6 | 100 | 124.51±13.30 | 117.34±13.33 | 116.50±23.51 | 114.78±26.11 | ||
硫氮卓酮 | 5.0mg | 10.41±2.51 | 9.21±2.85* | 7.66±1.65** | 7.11±1.29** | 7.82±3.11 | |
n=7 | 100 | 91.31±7.06 | 76.39±6.51 | 72.97±10.95 | 83.28±18.75 | ||
氧利用率 | 生理盐水 | 5.0ml | 71.25±5.99 | 68.89±9.35 | 68.99±5.91 | 69.71±9.79 | 71.53±8.16 |
n=6 | 100 | 96.67±10.17 | 97.04±6.76 | 98.19±3.46 | 100.64±10.76 | ||
本发明口服液 | 5.0g | 46.86±16.20 | 50.53±15.21 | 45.10±13.48 | 50.98±13.23 | 45.81±15.60 | |
n=6 | 100 | 109.99±17.23 | 97.47±7.53 | 113.52±30.85 | 99.69±22.32 | ||
本发明口服液 | 10.0g | 59.46±12.41 | 62.82±10.88 | 61.16±9.46 | 54.96±14.51 | 58.12±10.32 | |
n=6 | 100 | 107.70±21.36 | 104.37±13.14 | 95.7±29.19 | 101.76±28.38 | ||
硫氮卓酮 | 5.0mg | 57.58±11.81 | 37.53±7.87** | 38.61±6.28** | 42.59±17.33 | 48.76±20.12 | |
n=7 | 100 | 67.65±19.97## | 62.04±16.34## | 76.29±28.94 | 92.64±38.81 |
注:给药前后自身比较*P<0.05 **P<0.01与生理盐水组比较##P<0.01
实施例1:取以下原料:
黄芪300g 莪术250g 黄精300g 丹参250g
川芎250g 当归200g 延胡索250g 乌药200g以上八味,当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml,加入药液总量0.3%吐温-80增溶,备用,蒸馏后药液另器收集。丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12(50℃),以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用。提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇继续浓缩至相对密度1.15~1.18(50℃),加入上述丹参脂溶性提取部位,煮沸,放冷滤过,滤液中加入重蒸馏芳香水,加蒸馏水调至总量,用40%NaOH溶液调pH至7,加0.2%山梨酸,分装,灭菌,即得。
实施例2:取以下原料:
黄芪400g 莪术200g 黄精200g 丹参200g
川芎200g 当归150g 延胡索350g 乌药300g以上八味,当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml,加入药液总量0.3%吐温-80增溶,备用,蒸馏后药液另器收集。丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12(50℃),以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用。提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇继续浓缩至相对密度1.15~1.18(50℃),加入上述丹参脂溶性提取部位,煮沸,放冷滤过,滤液中加入重蒸馏芳香水,加蒸馏水调至总量,用40%NaOH溶液调pH至7,加0.2%山梨酸,分装,灭菌,即得。
实施例3:取以下原料:
黄芪350g 莪术250g 黄精250g 丹参250g
川芎200g 当归200g 延胡索300g 乌药200g以上八味,当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml,加入药液总量0.3%吐温-80增溶,备用,蒸馏后药液另器收集。丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12(50℃),以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用。提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇继续浓缩至相对密度1.15~1.18(50℃),加入上述丹参脂溶性提取部位,煮沸,放冷滤过,滤液中加入重蒸馏芳香水,加蒸馏水调至总量,用40%NaOH溶液调pH至7,加0.2%山梨酸,分装,灭菌,即得。
实施例4:取以下原料:
黄芪(200)g 莪术(300)g 黄精(300)g 丹参(300)
g
川芎(300)g 当归(150)g 延胡索(300)g 乌药(150)
g
按以下方法制备成颗粒剂:
以上八味,当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml备用,蒸馏后药液另器收集。丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12(50℃),以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用。提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,加入上述丹参脂溶性提取部位,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇并浓缩至稠膏状,加辅料适量,混匀,60℃以下干燥,喷加芳香水,制成颗粒,即得。
实施例5:取以下原料:
黄芪(500)g 莪术(200)g 黄精(200)g 丹参(250)g
川芎(200)g 当归(150)g 延胡索(350)g 乌药(150)g
按以下方法制备成胶囊剂:取以下原料:
以上八味,当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml备用,蒸馏后药液另器收集。丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12(50℃),以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用。提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,加入上述丹参脂溶性提取部位,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇并浓缩至稠膏状,加辅料适量,混匀,制成颗粒,60℃以下干燥,喷加芳香水,混匀,装胶囊,制成1000粒,即得。
实施例6:取以下原料:
黄芪550g 莪术200g 黄精200g 丹参250g
川芎150g 当归150g 延胡索350g 乌药150g
按以下方法制备成胶囊剂:取以下原料:
以上八味,当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml备用,蒸馏后药液另器收集。丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12(50℃),以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用。提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,加入上述丹参脂溶性提取部位,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇并浓缩至稠膏状,加辅料适量,混匀,60℃以下干燥,喷加芳香水制成颗粒,压片,即得。
Claims (6)
1、一种治疗冠心病的药物,其特征在于:它是由下述重量配比的原料组成的药剂:
黄芪1-12份、莪术1-10份、黄精1-12份、丹参1-10份、
川芎1-10份、当归1-8份、延胡索1-10份、乌药1-8份。
2、根据权利要求1所述的治疗冠心病的药物,其中各原料的重量配比是:
黄芪2-10份、莪术2-8份、黄精2-10份、丹参2-8份、
川芎2-8份、当归2-6份、延胡索2-8份、乌药2-6份。
3、根据权利要求1所述的治疗冠心病的药物,其中各原料的重量配比是:
黄芪6份、莪术5份、黄精6份、丹参5份、
川芎5份、当归4份、延胡索5份、乌药4份。
4、根据权利要求1、2或3所述的治疗冠心病的药物,其特征在于所说的
药剂是口服剂型。
5、根据权利要求4所述的治疗冠心病的药物,其特征在于所说的药剂是口服液。
6、权利要求5所述的治疗冠心病的药物的制备方法,其特征在于:取当归、川芎、莪术三味以水蒸汽蒸馏法提取,收集药材重4倍量芳香水,芳香水重蒸馏至250ml,加入药液总量0.3%吐温-80增溶,备用,蒸馏后药液另器收集;丹参以8倍量80%乙醇作溶媒,回流两次,第一次1.5h,第二次1h,滤过,合并滤液减压回收乙醇并浓缩至相对密度1.10~1.12,温度50℃,以总药液量0.5%吐温-80搅拌增溶,滤过,滤液另置备用;提取芳香水后药渣与丹参回流提取后药渣和处方中黄芪等四味加12倍水,煎煮三次,第一次1.5小时,第二次1小时,第三次1小时,合并水提液及上述蒸馏后药液,滤过,滤液浓缩至相对密度1.06~1.08,调含醇量至60%,静置24小时,取上清液,减压回收乙醇继续浓缩至相对密度1.15~1.18,温度50℃,加入上述丹参脂溶性提取部位,煮沸,放冷滤过,滤液中加入重蒸馏芳香水,加蒸馏水调至总量,用40%NaOH溶液调pH至7,加0.2%山梨酸,分装,灭菌,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02128080 CN1248722C (zh) | 2002-12-24 | 2002-12-24 | 治疗冠心病的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02128080 CN1248722C (zh) | 2002-12-24 | 2002-12-24 | 治疗冠心病的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1437964A CN1437964A (zh) | 2003-08-27 |
CN1248722C true CN1248722C (zh) | 2006-04-05 |
Family
ID=27672174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02128080 Expired - Fee Related CN1248722C (zh) | 2002-12-24 | 2002-12-24 | 治疗冠心病的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1248722C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491958B (zh) * | 2015-09-08 | 2020-04-17 | 上海中医药大学附属曙光医院 | 治疗冠心病心绞痛的中药复方制剂及其制备方法 |
-
2002
- 2002-12-24 CN CN 02128080 patent/CN1248722C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1437964A (zh) | 2003-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1317027C (zh) | 一种治疗抑郁症的中药 | |
CN100382839C (zh) | 一种治疗冠心病的中药组合物 | |
CN1742939A (zh) | 一种治疗肺间质纤维化的药物及其制备方法 | |
CN101433689A (zh) | 葛根薤白口服液及制备方法 | |
CN1167452C (zh) | 治疗艾滋病的药 | |
CN101057942A (zh) | 一种治疗糖尿病足的外用药膏及其制备方法 | |
CN100398139C (zh) | 一种治疗冠心病的中药制剂及其制备方法 | |
CN100348232C (zh) | 一种治疗心律失常的中药组合物 | |
CN1248722C (zh) | 治疗冠心病的药物及其制备方法 | |
CN1279944C (zh) | 用于治疗心脑血管系统疾病及供血不足的药物、药物制备方法及制剂 | |
CN1244353C (zh) | 治疗痤疮的药物及其制备方法 | |
CN1302799C (zh) | 一种治疗病毒性心肌炎的口服中药组合物 | |
CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
CN102552520A (zh) | 一种治疗胸痹心痛的活血止痛药物及制备工艺和应用 | |
CN1292766C (zh) | 一种治疗病毒性心肌炎的中药制剂及其制备方法 | |
CN1907345A (zh) | 一种治疗脑中风的中药组合物 | |
CN1086586C (zh) | 治疗心脑血管病的药物及其制备方法 | |
CN1915400A (zh) | 治疗鼻渊病症的药物 | |
CN103520474A (zh) | 一种治疗病毒性心肌炎的中药制剂 | |
CN1123354C (zh) | 一种治疗肺心病的药物 | |
CN102600422B (zh) | 一种治疗缓解期心绞痛的中药合剂 | |
CN1520859A (zh) | 治疗心脑血管病的丹红注射液 | |
CN100339093C (zh) | 一种治疗冠心病、心绞痛的复方药物及其制备方法 | |
CN101040920A (zh) | 一种治疗肾脏病的药物及其制备方法 | |
CN1853711A (zh) | 一种心脉康中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |